Log in

OTCMKTS:BLUSFBELLUS Health Stock Price, Forecast & News

$3.40
-8.62 (-71.71 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.52
Now: $3.40
$4.45
50-Day Range
$8.01
MA: $9.97
$12.02
52-Week Range
$0.49
Now: $3.40
$2.60
Volume111.09 million shs
Average Volume61,933 shs
Market Capitalization$541.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55
BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BLUSF
CUSIPN/A
CIKN/A
Phone45-0680-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30,000.00
Price / Sales18,033.60
Book Value$0.25 per share

Profitability

Net Income$-7,010,000.00
Net Margins-49,910.34%

Miscellaneous

Employees10
Market Cap$541.01 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BLUSF News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUSF and its competitors with MarketBeat's FREE daily newsletter.

BELLUS Health (OTCMKTS:BLUSF) Frequently Asked Questions

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc (OTCMKTS:BLUSF) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01. The firm had revenue of $0.01 million for the quarter. BELLUS Health had a negative return on equity of 48.37% and a negative net margin of 49,910.34%. View BELLUS Health's earnings history.

Has BELLUS Health been receiving favorable news coverage?

News articles about BLUSF stock have been trending negative on Wednesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BELLUS Health earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about BELLUS Health.

Who are some of BELLUS Health's key competitors?

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:
  • Roberto Bellini, President, Chief Executive Officer & Director
  • François Desjardins, Vice President-Finance
  • Denis Garceau, Senior Vice President-Drug Development
  • Tony Matzouranis, Vice President-Business Development
  • Sébastien Roy, Secretary

What is BELLUS Health's stock symbol?

BELLUS Health trades on the OTCMKTS under the ticker symbol "BLUSF."

How do I buy shares of BELLUS Health?

Shares of BLUSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BELLUS Health's stock price today?

One share of BLUSF stock can currently be purchased for approximately $3.40.

How big of a company is BELLUS Health?

BELLUS Health has a market capitalization of $541.01 million and generates $30,000.00 in revenue each year. BELLUS Health employs 10 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company can be reached via phone at 45-0680-4500 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.